Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - linagliptin 2.5mg;  ; metformin hydrochloride 1000mg - film coated tablet - 2.5 mg/1000 mg - active: linagliptin 2.5mg   metformin hydrochloride 1000mg excipient: arginine colloidal silicon dioxide copovidone hypromellose iron oxide red magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - linagliptin 2.5mg;  ; metformin hydrochloride 500mg - film coated tablet - 2.5 mg/500 mg - active: linagliptin 2.5mg   metformin hydrochloride 500mg excipient: arginine colloidal silicon dioxide copovidone hypromellose iron oxide yellow magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - linagliptin 2.5mg;  ; metformin hydrochloride 850mg - film coated tablet - 2.5 mg/850 mg - active: linagliptin 2.5mg   metformin hydrochloride 850mg excipient: arginine colloidal silicon dioxide copovidone hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Namibia - inglés - Namibia Medicines Regulatory Council

ingelheim pharmaceuticals (pty) ltd - linagliptin, metformin hydrochloride - tablet - each film-coated tablet contains; linagliptin 2,5 mg, metformin hydrochloride 500,0 mg

Namibia - inglés - Namibia Medicines Regulatory Council

ingelheim pharmaceuticals (pty) ltd - linagliptin, metformin hydrochloride - tablet - each film-coated tablet contains; linagliptin 2,5 mg, metformin hydrochloride 850,0 mg

Namibia - inglés - Namibia Medicines Regulatory Council

ingelheim pharmaceuticals (pty) ltd - linagliptin, metformin hydrochloride - tablet - each film-coated tablet contains; linagliptin 2,5 mg, metformin hydrochloride 1000,0 mg

Kenia - inglés - Pharmacy and Poisons Board

linagliptin inn 5mg - tablet - linagliptin inn 5mg - linagliptin

Kenia - inglés - Pharmacy and Poisons Board

metformin hydrochloride bp 500mg and linagliptin… - tablet - metformin hydrochloride bp 500mg and linagliptin… - metformin and linagliptin

Kenia - inglés - Pharmacy and Poisons Board

linagliptin inn - film-coated tablet - linagliptin inn 5 mg /tablet - linagliptin

Kenia - inglés - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no - linagliptin - tablet - linagliptin 5mg - linagliptin